Cigarette Smoke-derived Electrophilic Aldehydes and Airway Inflammation

香烟烟雾衍生的亲电醛与气道炎症

基本信息

项目摘要

DESCRIPTION (provided by applicant): Cigarette smoking remains a major global health burden and is strongly associated with increased childhood respiratory infections and development of chronic lung diseases such as COPD, asthma and lung cancer. The adverse health effects of cigarette smoke (CS) are largely related to its immuno-suppressive properties leading to impaired innate immune responses, host defense, and tumor surveillance. Although it is commonly thought that these effects are due to CS-derived reactive oxygen species (ROS), largely based on observations of protective effects of thiol-based antioxidants, the main thiol-reactive agents within CS are acrolein (2,3- propenal) and other related unsaturated aldehydes. Our recent studies in mice have demonstrated immunosuppressive effects of acrolein on alveolar macrophages that mimic those of CS. Acute mechanisms associated with direct and transient alkylation of redox-sensitive protein targets appear to be critical in this respect, diretly affecting activation of NF-κB or AP-1 and altering cellular redox regulation. However, the specific functional consequences of these protein alkylations are not known. Acrolein exposure also mimics some of the variable effects of cigarette smoking on asthma development and severity, by promoting allergic sensitization but also by suppressing allergic inflammation. These effects of acrolein were associated with increased epithelial injury and are likely mediated by altered epithelial barrier integrity and interaction with dendritic cells, the main antigen-presentng cell in the lung, although the mechanisms by which acrolein impacts on epithelial integrity and production of mediators that regulate dendritic cell maturation are not known. The main goal of the present proposal is to elucidate the mechanisms by which acrolein alters innate macrophage and epithelial immune responses as well as allergic inflammation, and to identify the importance of direct alkylation of critical enzyme systems. We plan to determine the importance of direct protein modifications in acrolein-induced suppression of innate immune responses (Aim 1), using newly developed proteomic approaches and analysis of the functional importance of these modifications in target proteins, and explore the consequences of acrolein exposure on allergic inflammation and sensitization (Aim 2), focusing on alterations in epithelial barrier function and mediator production in association with direct alkylation or relevant target proteins. Also, based on recent studies indicating that acrolein is detoxified by glutathione S-transferase P1 (GSTP1) and by hydrogen sulfide (H2S), a newly recognized endogenous mediator produced by (homo)cysteine metabolism by cystathionine ß-synthase (CBS), we will explore the importance of GSTP1 and CBS/H2S in modulating acrolein-induced alterations in immune responses (Aim 3). Collectively, these studies will not only offer important insights into the potential contribution of acrolein to CS-related disease, but may also be relevant to understanding the actions of other relevant endogenous or environmental electrophiles.
描述(由适用提供):吸烟仍然是全球主要的健康燃烧,与儿童呼吸道感染和慢性肺部疾病(如COPD,哮喘和肺癌)的发展密切相关。香烟烟雾(CS)的不良健康影响与其免疫抑制特性有关,从而导致先天免疫调查,宿主防御和肿瘤监测受损。尽管通常认为这些作用是由于CS衍生的活性氧(ROS)引起的,这主要是基于对基于硫醇的抗氧化剂的保护作用的观察结果,但CS中的主要硫醇反应性剂是丙烯醛(2,3-丙烯酸酯)和其他相关的相关抗饱和醛。我们最近对小鼠的研究表明,丙烯醛对模仿CS的肺泡巨噬细胞的免疫抑制作用。与氧化还原敏感蛋白靶标的直接和瞬时烷基化相关的急性机制在这方面似乎至关重要,直接影响NF-κB或AP-1的激活并改变了细胞氧化还原的调节。但是,这些蛋白质酒精的特定功能后果尚不清楚。丙烯醛暴露还通过促进过敏敏感性,但也通过抑制过敏感染来模仿吸烟对哮喘发育和严重程度的一些可变影响。丙烯醛的这些作用与上皮损伤的增加有关,并且可能是通过改变肺中肺中的主要抗原特征细胞的上皮屏障完整性和与树突状细胞的相互作用介导的,尽管丙烯醛对上皮完整性的机制对上皮完整性和调节树突状细胞成熟的介体产生的机制尚不清楚。本提案的主要目的是阐明丙烯醛改变先天巨噬细胞和上皮免疫反应以及过敏性注射的机制,并确定关键酶系统直接酒精的重要性。我们计划使用新开发的蛋白质组学方法和分析这些修饰在靶蛋白中的功能重要性,并探索邻里蛋白蛋白暴露于过敏性和敏感性(AIM 2),探索邻际式和敏感性的影响(AIM 2),在丙烯酸蛋白质组中的抑制和敏感性(AIM 2)相关的阶级,在邻际式的目标上(AIM 2)探索了杂种型,在靶向蛋白质中的后果(AIM 2)蛋白质。 Also, based on recent studies indicating that acrolein is detoxified by glutathione S-transferase P1 (GSTP1) and by hydrogen sulfide (H2S), a newly recognized endogenous mediator produced by (homo)cysteine ​​metabolism by cystathionine ß-synthase (CBS), we will explore the importance of GSTP1 and CBS/H2S in modulating丙烯醛诱导的免疫反应改变(AIM 3)。总的来说,这些研究不仅会为丙烯醛对CS相关疾病的潜在贡献提供重要的见解,而且还可能与理解其他相关内源性或环境电力的作用有关。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALBERT VAN DER VLIET其他文献

ALBERT VAN DER VLIET的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALBERT VAN DER VLIET', 18)}}的其他基金

DUOX1 in fibroblast-macrophage cross-talk in pulmonary fibrosis
肺纤维化中成纤维细胞-巨噬细胞串扰中的 DUOX1
  • 批准号:
    10544804
  • 财政年份:
    2022
  • 资助金额:
    $ 38.13万
  • 项目类别:
DUOX1 in fibroblast-macrophage cross-talk in pulmonary fibrosis
肺纤维化中成纤维细胞-巨噬细胞串扰中的 DUOX1
  • 批准号:
    10353646
  • 财政年份:
    2022
  • 资助金额:
    $ 38.13万
  • 项目类别:
NOX Family NADPH Oxidases GRC/GRS
NOX 家族 NADPH 氧化酶 GRC/GRS
  • 批准号:
    10463998
  • 财政年份:
    2022
  • 资助金额:
    $ 38.13万
  • 项目类别:
DUOX1 and Mitochondria in Obese Asthma
肥胖哮喘中的 DUOX1 和线粒体
  • 批准号:
    9386934
  • 财政年份:
    2017
  • 资助金额:
    $ 38.13万
  • 项目类别:
DUOX1 Silencing in Age-Related COPD
年龄相关性 COPD 中的 DUOX1 沉默
  • 批准号:
    9262578
  • 财政年份:
    2017
  • 资助金额:
    $ 38.13万
  • 项目类别:
Cigarette Smoke-derived Electrophilic Aldehydes and Airway Inflammation
香烟烟雾衍生的亲电醛与气道炎症
  • 批准号:
    8484841
  • 财政年份:
    2012
  • 资助金额:
    $ 38.13万
  • 项目类别:
Cigarette Smoke-derived Electrophilic Aldehydes and Airway Inflammation
香烟烟雾衍生的亲电醛与气道炎症
  • 批准号:
    8628126
  • 财政年份:
    2012
  • 资助金额:
    $ 38.13万
  • 项目类别:
Cigarette Smoke-derived Electrophilic Aldehydes and Airway Inflammation
香烟烟雾衍生的亲电醛与气道炎症
  • 批准号:
    8272910
  • 财政年份:
    2012
  • 资助金额:
    $ 38.13万
  • 项目类别:
Dual Oxidase in Airway Epithelial Repair and Remodeling
双氧化酶在气道上皮修复和重塑中的作用
  • 批准号:
    7808841
  • 财政年份:
    2008
  • 资助金额:
    $ 38.13万
  • 项目类别:
Dual Oxidase in Airway Epithelial Repair and Remodeling
双氧化酶在气道上皮修复和重塑中的作用
  • 批准号:
    7533224
  • 财政年份:
    2008
  • 资助金额:
    $ 38.13万
  • 项目类别:

相似国自然基金

DUSP2介导自噬调控气管上皮细胞炎症在急性肺损伤中的机制研究
  • 批准号:
    82360379
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
基于巨噬细胞炎性小体活化探究木犀草素治疗急性肺损伤的新机制
  • 批准号:
    82374186
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
CDK4/6抑制下调衰老中性粒细胞促炎效应改善急性肺损伤的机制和干预研究
  • 批准号:
    82302445
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
ACSS2介导的乙酰辅酶a合成在巨噬细胞组蛋白乙酰化及急性肺损伤发病中的作用机制研究
  • 批准号:
    82370084
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
基于肺间充质干细胞源外泌体lncRNA表达谱差异探讨益气活血解毒法改善脓毒症急性肺损伤的机制
  • 批准号:
    82374400
  • 批准年份:
    2023
  • 资助金额:
    51 万元
  • 项目类别:
    面上项目

相似海外基金

Pathophysiological Mechanisms of Chemical-Induced Acute Lung Injury
化学引起的急性肺损伤的病理生理机制
  • 批准号:
    10708438
  • 财政年份:
    2023
  • 资助金额:
    $ 38.13万
  • 项目类别:
Cellular and molecular mechanisms of e-cigarette vaping-induced acute lung injury
电子烟引起急性肺损伤的细胞和分子机制
  • 批准号:
    10690279
  • 财政年份:
    2022
  • 资助金额:
    $ 38.13万
  • 项目类别:
Improving our mechanistic understanding of Electronic-cigarette, or vaping, product use-associated lung injury
提高我们对电子烟或电子烟产品使用相关肺损伤的机制理解
  • 批准号:
    10115186
  • 财政年份:
    2020
  • 资助金额:
    $ 38.13万
  • 项目类别:
Advanced TRPA1 Inhibitor for the Treatment of Chlorine Inhalation Injury
用于治疗氯吸入损伤的先进 TRPA1 抑制剂
  • 批准号:
    10247523
  • 财政年份:
    2019
  • 资助金额:
    $ 38.13万
  • 项目类别:
Advanced TRPA1 Inhibitor for the Treatment of Chlorine Inhalation Injury
用于治疗氯吸入损伤的先进 TRPA1 抑制剂
  • 批准号:
    10002221
  • 财政年份:
    2019
  • 资助金额:
    $ 38.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了